Sionna Therapeutics, INC. (SION) — SEC Filings

Overview

Sionna Therapeutics, INC. (SION) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 22, 2026: On April 17, 2026, Peter A. Thompson reported a change in beneficial ownership of securities for Sionna Therapeutics, Inc. The filing, dated April 21, 2026, details these changes as per SEC regulations.

Sentiment Summary

Across 15 filings, the sentiment breakdown is: 1 bearish, 13 neutral, 1 mixed. The dominant filing sentiment for Sionna Therapeutics, INC. is neutral.

Filing Type Overview

Sionna Therapeutics, INC. (SION) has filed 4 4, 3 10-Q, 4 8-K, 1 DEF 14A, 1 10-K, 1 S-1/A, 1 S-1 with the SEC between Jan 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (15)

• Sionna Therapeutics: Ownership Change Reported — 4 · Apr 22, 2026 Risk: low
  On April 17, 2026, Peter A. Thompson reported a change in beneficial ownership of securities for Sionna Therapeutics, Inc. The filing, dated April 21, 2026, det
• 4 Filing — 4 · Apr 22, 2026
• Sionna Therapeutics Files Form 4 — 4 · Apr 16, 2026 Risk: low
  On April 16, 2026, Sionna Therapeutics, Inc. filed a Form 4, indicating a change in beneficial ownership of securities. The filing pertains to the period of rep
• 4 Filing — 4 · Apr 16, 2026
• Sionna's Losses Mount Amid R&D Spend, Capital Infusion — 10-Q · Nov 5, 2025 Risk: high
  Sionna Therapeutics, Inc. (SION) reported a net loss of $54.8 million for the nine months ended September 30, 2025, an increase from $45.8 million for the same
• Sionna's Q2 Losses Widen to $45.3M Amid R&D Push — 10-Q · Aug 11, 2025 Risk: high
  Sionna Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical com
• Sionna Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025 Risk: low
  Sionna Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders on June 12, 2025. The filing indicates the
• Sionna Therapeutics Files 8-K — 8-K · Jun 4, 2025 Risk: low
  Sionna Therapeutics, Inc. filed an 8-K on June 4, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company,
• Sionna Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
  Sionna Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, located at 21 Hickory Drive, Suite 500, Waltham, MA, ope
• Sionna Therapeutics Files Proxy Statement for June Meeting — DEF 14A · Apr 29, 2025 Risk: low
  Sionna Therapeutics, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 12, 2025. The company, incorporated in Delaware
• 10-K Filing — 10-K · Mar 20, 2025
• Sionna Therapeutics Files 8-K on Financials — 8-K · Mar 20, 2025 Risk: low
  Sionna Therapeutics, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Sionna Therapeutics Files 8-K for Corporate Updates — 8-K · Feb 10, 2025 Risk: low
  Sionna Therapeutics, Inc. filed an 8-K on February 10, 2025, reporting an event that occurred on February 6, 2025. The filing pertains to amendments to its arti
• Sionna Therapeutics Files S-1/A Amendment — S-1/A · Feb 3, 2025 Risk: medium
  Sionna Therapeutics, Inc. filed an S-1/A amendment on February 3, 2025, for its initial public offering. The company, incorporated in Delaware, is based in Walt
• Sionna Therapeutics Files for IPO — S-1 · Jan 17, 2025 Risk: high
  Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, filed an S-1 registration statement on January 17, 2025, to potentially raise capital thr

Related Companies

VRTX

Frequently Asked Questions